Table 9.

Claim categories for higher generation antibody patents

Category	Example IP rights	Assignee	Target	Claim language
2nd medical use	EP1734996B1	University of California	α vbeta 5 integrin	Use of an antibody that specifically binds to α vbeta 5 integrin, wherein the antibody is a humanized form of the antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817, for the manufacture of a medicament for treating pulmonary edema.
Dosage patent	EP1210115B1*	Genentech	HER2	Use of the anti-ErbB2 antibody huMab 4D5 for treating a human patient diagnosed with a breast cancer characterized by overexpression of ErbB2, said method comprising the steps of administering to the patient an initial dose of 8mg/kg of the anti-ErbB2 antibody; and administering to the patient a plurality of subsequent doses of the antibody in an amount that is 6 mg/kg, wherein the doses are separated in time from each other by 3 weeks.
Formulation	EP2459167B1	Roche	HER2	A highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody for subcutaneous injection comprising:a. about 50 to 350 mg/ml anti-HER2 antibody;b. about 1 to 100 mM of a buffering agent providing a pH of 5.5 ± 2.0;c. about 1 to 500 mM of a stabilizer or a mixture of 2 or more stabilizers;d. about 0.01 to 0.08 % of a nonionic surfactant; ande. more than 150 to about 16′000 U/ml, about 2′000 U/ml, or about 12′000 U/ml, respectively of a hyaluronidase enzyme.

^*EP Patent revoked in opposition, appeal pending. In UK finally revoked.